Bio-Techne Corp (TECH) News
Filter TECH News Items
TECH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
TECH News Highlights
- TECH's 30 day story count now stands at 3.
- Over the past 7 days, the trend for TECH's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about TECH are BIO, DRUG and IR.
Latest TECH News From Around the Web
Below are the latest news stories about BIO-TECHNE CORP that investors may wish to consider to help them evaluate TECH as an investment opportunity.
BIO-TECHNE TO PRESENT AT THE 42nd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCEBio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, current Chief Operating Officer, and Chief Executive Officer effective February 1, 2024, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:00 a.m. PST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. |
BIO-TECHNE ANNOUNCES SUBMISSION OF FDA DRUG MASTER FILE FOR EXCELLERATE GMP IPSC EXPANSION MEDIUM SUPPORTING STEM CELL THERAPYBio-Techne Corporation (NASDAQ: TECH) today announced that it has filed a Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for its ExCellerate™ GMP iPSC Expansion Medium, Animal Free (CCM0036-GMP), supporting the development and manufacture of regenerative medicine and stem cell therapies. |
LUNAPHORE AND SIB AWARDED INNOSUISSE FUNDING TO DEVELOP INNOVATIVE AI-BASED ASSAY DEVELOPMENT TOOLSBio-Techne Corporation (NASDAQ: TECH) today announced that Lunaphore, a Bio-Techne brand, and SIB Swiss Institute of Bioinformatics, have been awarded Innosuisse funding for an innovation project. The collaboration aims to develop novel AI-based assay development tools for spatial biology on Lunaphore's COMET™ to further accelerate the adoption of multiplex sequential immunofluorescence (seqIF™) technology in research. |
Should You Hold Bio-Techne Corporation (TECH) For the Long Term?Fred Alger Management, an investment management company, released its “Alger Small Cap Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. In the third quarter, the fund outperformed the Russell 2000 Growth Index. The Information Technology and Healthcare sectors contributed to the fund’s relative performance in the quarter, […] |
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCEBio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. |
Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)Key Insights Bio-Techne's estimated fair value is US$57.87 based on 2 Stage Free Cash Flow to Equity With US$63.58... |
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCESBio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: |
ASURAGEN TO PRESENT NOVEL CLINICAL TESTING DATA AT AMP 2023 CONFERENCEBio-Techne Corporation (NASDAQ:TECH) today announced that Asuragen, a Bio-Techne brand, will present new data on clinical laboratory testing solutions related to cystic fibrosis variant detection, cancer monitoring, resolving conventionally inaccessible, disease-causing genes, and more at the upcoming meeting of the Association for Molecular Pathology (AMP), to be held November 14-18 in Salt Lake City, Utah. Attendees can learn about Asuragen's new products and innovations through a series of co |
Bio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Call TranscriptBio-Techne Corporation (NASDAQ:TECH) Q1 2024 Earnings Call Transcript October 31, 2023 Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2024. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Techne’s Vice President, Investor Relations. David Clair: Good morning, and thank […] |
Bio-Techne Corp (TECH) Reports 2% Organic Revenue Growth in Q1 FY2024GAAP Earnings Per Share Drops to $0.31 from $0.55 in the Previous Year |